Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424321 | 1.00 | EPHX2 (0.33) | EPHX2ACHEPDE10AMEN1KMT2A | |
| SCHEMBL14717289 | 0.84 | — | — | |
| SCHEMBL31479150 | 0.81 | EPHX2 (0.36) | EPHX2PDE10A | |
| SCHEMBL12385988 | 0.79 | EPHX2 (0.35) | EPHX2ACHE | |
| SCHEMBL15655579 | 0.75 | TRPC3 (0.35) | EPHX2ACHE | |
| SCHEMBL15655580 | 0.75 | TRPC3 (0.35) | EPHX2ACHE | |
| SCHEMBL12384407 | 0.74 | EPHX2 (0.33) | EPHX2ACHEMEN1KMT2A | |
| SCHEMBL31479181 | 0.71 | EPHX2 (0.40) | EPHX2MEN1KMT2A | |
| SCHEMBL1991683 | 0.71 | MEN1 (0.38) | EPHX2ACHEMEN1KMT2A | |
| SCHEMBL31479347 | 0.70 | EPHX2 (0.36) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | EPHX2 669/4885ACHE 3858/4885PDE10A 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.